Halo-Bio RNAi Therapeutics
Halo Bio is a biotechnology company focused on developing innovative RNAi-based biopharmaceuticals. Their platform integrates RNA Core, RNA Shells, and Particle Shells to create targeted, bioavailable nanoparticle medicines for treating human diseases, including viral infections like SARS-2. They aim to overcome delivery challenges in RNA therapeutics and develop rapid-response treatments for viral outbreaks.
Industries
Nr. of Employees
small (1-50)
Halo-Bio RNAi Therapeutics
Washington, District of Columbia, United States, North America
Products
RNA nanoparticle therapeutic platform (self-assembling core + programmable shell)
A platform architecture combining a self-assembling single-stranded RNA core that functions as the active ingredient with a programmable aptamer-driven protein shell to enable tissue targeting and intracellular delivery.
Antiviral replicating RNA therapeutic candidate (respiratory delivery)
Design-stage replicating subviral RNA constructs intended to suppress viral mRNA expression in infected cells; candidates are being prepared for production and preclinical testing and considered for intrapulmonary or nasal delivery.
RNA nanoparticle therapeutic platform (self-assembling core + programmable shell)
A platform architecture combining a self-assembling single-stranded RNA core that functions as the active ingredient with a programmable aptamer-driven protein shell to enable tissue targeting and intracellular delivery.
Antiviral replicating RNA therapeutic candidate (respiratory delivery)
Design-stage replicating subviral RNA constructs intended to suppress viral mRNA expression in infected cells; candidates are being prepared for production and preclinical testing and considered for intrapulmonary or nasal delivery.
Services
Custom RNA design and computational candidate development
Computational design and sequence engineering of multivalent RNA triggers and self-assembling RNA cores for target gene suppression and candidate generation.
Scalable cell-free manufacturing and formulation services
Production and formulation of RNA nanoparticle candidates using scalable cell-free systems, including plant cell-free platforms, and formulation into VLP or lipoplex vehicles.
Collaborative licensing and partnership engagements
Licensing and partnership arrangements to access RNA sequences, peptide/protein surfaces, or co-develop pipeline candidates.
Custom RNA design and computational candidate development
Computational design and sequence engineering of multivalent RNA triggers and self-assembling RNA cores for target gene suppression and candidate generation.
Scalable cell-free manufacturing and formulation services
Production and formulation of RNA nanoparticle candidates using scalable cell-free systems, including plant cell-free platforms, and formulation into VLP or lipoplex vehicles.
Collaborative licensing and partnership engagements
Licensing and partnership arrangements to access RNA sequences, peptide/protein surfaces, or co-develop pipeline candidates.
Expertise Areas
- RNAi therapeutic design
- Self-assembling RNA nanoparticle engineering
- Nanoparticle surface engineering with aptamers
- Antiviral RNA therapeutics
Key Technologies
- RNA interference (RNAi)
- Multivalent RNA triggers
- Self-assembling single-stranded RNA nanoparticles
- Aptamer-directed protein surfaces